REGN5458 Bispecific Antibody | Naresh Bumma, MD | IMS 2022

REGN5458 Bispecific Antibody | Naresh Bumma, MD | IMS 2022
Fit Vs. Frail & Smoldering Myeloma | María-Victoria Mateos, MD, PhD | IMS 2022
What AML mutations benefit from targeted therapy?
What is the difference between chemotherapy and targeted therapy?
What are the current treatment options available for patients with AML?
How likely is it that MDS will progress to AML? and how long does it usually take?